Epidemiology
Dengue is a mosquito-borne viral disease that is endemic in most tropical and sub-tropical countries. Epidemics were described in Australia, Asia, the Americas, the Pacific and the Caribbean in the 18th and 19th centuries and outbreaks described in central America and the Caribbean in the 17th century are also believed to be dengue 1 . Increased incidence of dengue and emergence of dengue haemorrhagic fever in Southeast Asia in the second half of the 20th century was a consequence of uncontrolled urbanisation, human movement and population growth during the Second World War.
The incidence has continued to increase dramatically since that time and dengue is now endemic in more than 100 tropical and subtropical countries, where the principal mosquito vectors Aedes aegypti ( Figure 1) 
Clinical features
Infection with any of the four dengue viruses (DENV-1-4) causes a spectrum of illness ranging from a mild or severe acute flu-like illness known as dengue fever (DF) to severe dengue (previously known as dengue hemorrhagic fever and dengue shock syndrome) 7 . Symptoms become apparent 4-10 days after the bite of an infected mosquito and usually last for 2-7 days. In up to 20% of cases decrease in fever is accompanied by sudden onset of complications due to a vascular leak syndrome consisting of plasma leakage, severe bleeding, respiratory distress or organ impairment.
Medical care and maintenance of blood fluid volume during the 24-48 h critical phase can decrease mortality from more than 20%
to less than 1%. Warning signs that predict severe dengue are useful for deciding which patients need hospital admission and more intensive monitoring 8 ; however, they may not be recognised and case management may not be optimal, exposing patients to unnecessary risk 9 .
Dengue is an acute viral infection and virus can be detected in blood by RT-PCR or NS1 protein ELISA from disease onset for up to 9 days.
During the viremic phase infected people may transmit DENV to a susceptible host via the bite of the appropriate mosquito vector, after an extrinsic incubation period of 8-12 days following the blood meal during which the virus replicates within the mosquito and is amplified in the salivary glands.
Immune responses
Immunity to DENV infection is thought to be lifelong, and DENVspecific neutralising antibody responses have been detected more than 60 years after infection 9, 10 . Infection with one serotype does not protect against infection with the other three serotypes, and indeed epidemiological observations indicate secondary infection with heterologous DENV serotypes is associated with increased probability of severe dengue
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; 80-90% of severe dengue cases occur in individuals experiencing secondary infection with heterologous DENV.
DENV genomes and correlates of epidemic virulence
The . Ae. Albopictus is a less efficient DENV vector than Ae. aegypti 21 and under most conditions would be unlikely to be responsible for large-scale dengue outbreaks. This species is not known to be present in mainland Australia. 
Introduction of DENV in travellers

Conclusion
Surveillance of DENV imported by travellers provides information on origin and movement of DENV in the region and in countries where locally generated detailed genetic data may not be available.
Ongoing public health surveillance and rapid response measures are necessary to detect incursion of Ae. aegypti and Ae. Albopictus and to prevent re-introduction of dengue into states where the disease has not been present for many decades.
